logo

Enter Symbol
Community Research
Technical Charts
Analyst Ratings
Analyst Estimates
 
Sales Estimates
 
Related News
 
Technicals
 

TRANSGENOM(OTC:TBIO)
Transgenomic provides innovative research tools to the genomics segment of the life sciences industry. These tools enable researchers to discover and understand variations in the human genetic code. The company believes its WAVE System, which incorporates its proprietary DNASep separation column and associated software, chemical reagents and other consumable items, will become a leading tool to analyze genetic mutations. The WAVE System allows researchers to analyze both known and unknown genetic mutations faster, with more accuracy and at a lower cost than other techniques.
# Employees: 156
Address: 12325 Emmet Street,Omaha,NE,USA
Phone: 402 452-5400
Fax: 402 452-5447
Website: www.transgenomic.com
Email: investorrelations@transgenomic.com
Sector: Medical
Industry: MED INSTRUMENTS
Executive Officers
Collin J. D'Silva (Chmn.; C.E.O.; Dir.)
Mitchell L. Murphy (V.P.; Sec.; Treas.)
Michael A. Summers (C.F.O.)
Gregory J. Duman (Dir.)
Roland J. Santoni (Dir.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 3/17/2010
Mean EPS (Next Qtr): ($0.01)
Mean EPS (Year): ($0.01)
Mean Estimate(Long Term): ($0.01)
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 0
Shares Performance
Period TBIO Compare to S&P
YTD 47.73 % 22.25 %
4 Weeks 0.00 % -5.07 %
12 Weeks 22.64 % 14.20 %
Shares Information
Analyst Coverage: N
Avg Volume: 59262
Shares Outstanding: 49M
Market Cap: $0.03B
52 Week High: $0.74
52 Week Low: $0.21
P/E Ratio: -0.010
PEG Ratio: -0.010
Split: On 1/1/1990 TBIO split by factor of 0.040
Earnings Performance
EPS Growth in Last Quarter: 0.00 %
EPS Growth in Last Year: 0.00 %
Sales Growth in Last Quarter: -7.80 %
Sales Growth in Last Quarter: -5.98 %
Financials
Qtr Book Value: $2.78
Cash Flow/Share: ($0.01)
Change in Payout Ratio: -0.010
Price/Sales: 1.480
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia